How willing are the public to pay for anti-hypertensive drugs for primary prevention of cardiovascular disease: A survey in a Chinese city

International Journal of Epidemiology

Volumn 39, Issue 1, 2009, Pages 244-254

  Tang, Jin Ling ^a,b   Wang, Wei Zhong ^c   An, Jian Gang ^d   Hu, Yong Hua ^b   Cheng, Shi Hua ^d   Griffiths, Sian ^c  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^c and Hong Kong Branch of CAS Center for Excellence in Animal Evolution and Genetics   (Hong Kong)

^d BAOTOU MEDICAL COLLEGE   (China)

Author keywords

Cardiovascular disease; China; Evidence based policy; Hypertension; Willingness to pay

Indexed keywords

ANTIHYPERTENSIVE AGENT;

CARDIOVASCULAR DISEASE; DISEASE TREATMENT; DRUG PRESCRIBING; EPIDEMIOLOGY; GUIDELINE; HEALTH RISK; HYPERTENSION; PRIMARY HEALTH CARE; PUBLIC HEALTH; QUESTIONNAIRE SURVEY; WILLINGNESS TO PAY;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHINESE; CONTROLLED STUDY; DECISION MAKING; DRUG COST; FEMALE; HEALTH CARE COST; HEALTH SURVEY; HUMAN; HYPERTENSION; INTERVIEW; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; PRIMARY PREVENTION; PRIORITY JOURNAL; RURAL AREA; URBAN AREA; CHINA; COST BENEFIT ANALYSIS; CROSS-SECTIONAL STUDY; ECONOMICS; QUESTIONNAIRE; RURAL POPULATION; SOCIOECONOMICS; STATISTICS; URBAN POPULATION;

CHINA;

ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; CHINA; COST-BENEFIT ANALYSIS; CROSS-SECTIONAL STUDIES; HUMANS; HYPERTENSION; PRIMARY PREVENTION; QUESTIONNAIRES; RURAL POPULATION; SOCIOECONOMIC FACTORS; URBAN POPULATION;

EID: 77952302869     PISSN: 03005771     EISSN: 14643685     Source Type: Journal    
DOI: 10.1093/ije/dyp213     Document Type: Article

References (37)

1. Hu SL, Tang SL, Liu YL, Zhao YX, Escobar ML, de Ferranti D. Reform of how health care is paid for in China: challenges and opportunities. Lancet 2008;372: 1846-53.
2. Tang JL, Hu YH. Drugs for primary preventing cardiovascular disease in China: risk factor thresholds should vary according to resources. Br Med J 2005;330:610-11.
3. Eddy DM. Rationing by patient choice. JAMA 1991;265: 105-8.
4. Haynes B. Can it work? Does it work? Is it worth it? Br Med J 1999;319:652-53.
5. McCormack JP, Loewen P. Adding 'value' to clinical practice guidelines. Can Fam Physicians 2007;8:1326-27.
6. World Health Organization, International Society of Hypertension writing group. World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003; 21:1983-92.
7. Wallis EJ, Ramsay LE, Jackson PR. Cardiovascular and coronary risk estimation in hypertension management. Heart 2002;88:306-12.
8. MacMahon S, Neal B, Rodgers A. Hypertension-time to move on. Lancet 2005;365:1108-9.
9. Jackson R, Lawes CMM, Bennett DA, Milne RJ, Rodgers A. Treatment with drugs to lower blood pressure and blood cholesterol based on an individual's cardiovascular risk. Lancet 2005;365:434-41.
10. Williams B, Poultern NR, Brown MJ et al. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004BHS IV. J Hum Hypertens 2004;18:139-85.
11. European society of Hypertension-European society of Cardiology Guidelines Committee. European society of Hypertension-European society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003;21:1011-53.
12. Task Force Members. Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;6:1105-87.
13. Robson J, Boomla K, Hart B, Feder G. Estimating cardiovascular risk for primary prevention: Outstanding questions for primary care. Br Med J 2000;320:702-4.
14. The Committee for Revising the 1999 Chinese Guideline for Prevention and Treatment of Patients with Hypertension. Update: Chinese guidelines for prevention and treatment of patients with hypertension. Chin J Cardiol 2004;32:1060-64.
15. Eddy DM. Connecting value and costs: whom do we ask, and what do we ask them? JAMA 1990;264:1737-39.
16. Angell M. The Truth About the Drug Companies: How They Deceive Us and What To Do About It. New York: Random House Inc., 2004.
17. Blech J. Inventing Disease and Pushing Pills. London: Routledge Taylor & Francis Group, 2006.
18. Kearney PM, Whelton M, Reynolds K, Kearney PM, Whelton P. Worldwide prevalence of hypertension: a systematic review. J Hypertens 2004;22:11-19.
19. The Ministry of Health, the Ministry of Science and Technology, and the National Bureau of Statistics, the Peoples Republic of China. Nutrition and Health Status of the Chinese Population. Beijing: State Information Office, 2004.
20. http://www.baotou.gov.cn/zfsw/btmzj/gzdt_xs.asp?mid=22 (6 August 2007, date last accessed).
21. http://www.stats.gov.cn/tjgb/rkpcgb/dfrkpcgb/t20020331_15427.htm (6 August 2007, date last accessed).
22. http://www.btwsj.gov.cn/danweijianjie.asp (6 August 2007, date last accessed).
23. Malenka DJ, Baron JA, Johansen S, Wahrenberger JW, Ross JM. The framing effect of relative and absolute risk. J Gen Intern Med 1993;8:543-48.
24. Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. Br Med J 1995;310:452-54.
25. Steiner JF. Talking about treatment: the language of populations and the language of individuals. Ann Intern Med 1999;130:618-22.
26. Liu LS, Wang JG, Gong LS, Liu G, Staessen JA. Comparison of active treatment and placebo for older patients with isolated systolic hypertension. J Hypertens 1998;16:1823-29.
27. Chen Y, Wang M, Zhan SY et al. An analysis on the cost of hypertensive outpatients in community hospitals in Shanghai. Chin J Epidemiol 2003;12:1074-77.
28. Yang XH, Li HY, Yao CH. Analysis of cost and relevant factors in antihypertensive treatment for outpatients with hypertension in Beijing. Chin J Gen Pract 2005;9:528-31.
29. The National Bureau of Statistics of China, China Statistical Yearbook-2004, http://www.stats.gov.cn/tjgb/ndtjgb/qgndtjgb/t20050228_402231854.htm (6 August 2007, date last accessed).
30. Cranney M, Warren E, Walley T. Hypertension in the elderly: attitudes of British patients and general practitioners. J Hum Hypertens 1998;12:539-45.
31. Frijling BD, Lobo CM, Keus IM et al. Perceptions of cardiovascular risk among patients with hypertension or diabetes. Patient Educ Couns 2004;52:47-53.
32. National Health Committee. Guidelines for the Management of Mildly Raised Blood Pressure in New Zealand. Wellington: Ministry of Health, 1995.
33. Steel N. Thresholds for taking antihypertensive drugs in different professional and lay groups: questionnaire survey. Br Med J 2000;320:1446-47.
34. Nicholson K, Ramsay LE, Haq IU, Wallis EJ, Ghahramani P, Jackson PR. Factors affecting the acceptance of drug therapy to prevent myocardial infarction. Br J Clin Pharmacol 1999;47:580.
35. Hux JE, Naylor CD. Communicating the benefits of chronic preventive therapy: does the format of efficacy data determine patients' acceptance of treatment? Med Decis Making 1995;15:152-57.
36. Diener A, O'Brien B, Gafni A. Health care contingent valuation studies: a review and classification of the literature. Health Econ 1998;7:313-26.
37. Wang WZ. Knowledge, attitude, perception and willingness to pay regarding antihypertensive treatment: A survey of the public and physicians in China. Ph.D. Thesis. The Chinese University of Hong Kong, Hong Kong, 2006.